Brainstorm Cell Therapeutics (BCLI) Misses Q3 EPS by 176c

Brainstorm Cell Therapeutics (NASDAQ: BCLI) reported Q3 EPS of ($1.80), $1.76 worse than the analyst estimate of ($0.04).

For earnings history and earnings-related data on Brainstorm Cell Therapeutics (BCLI) click here.

You May Also Be Interested In

• Freedom Broker Downgrades Nucor (NUE) to Hold, 'Guides Conservative Earnings Yet Again'
• U.S. military had close call after using AI for false intelligence report - CNN
• Corpay agrees to $100M FTC settlement over marketing practices